ADH-1
Based on 10 publication(s) in Google Scholar
ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.62%
- No. CAS: 229971-81-7
- Fòrmula: C22H34N8O6S2
- Peso molecular:570.69
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ADH-1
More- Cell Death Dis. 2022 Jun 20;13(6):557. [Abstract]
- Oncogene. 2022 Nov;41(46):5020-5031. [Abstract]
- Sci Rep. 2019 Feb 6;9(1):1517. [Abstract]
- J Cell Mol Med. 2022 Apr;26(8):2392-2403. [Abstract]
- iScience. 2024 Feb 6;27(3):109119. [Abstract]
- J Pain Res. 2020 Aug 12;13:2065-2072. [Abstract]
- Biochem Biophys Res Commun. 2019 Oct 5. pii: S0006-291X(19)31851-0. [Abstract]
- bioRxiv. 2025 Oct 3.
- bioRxiv. 2025 Oct 24.
- bioRxiv. 2023 Jul 25:2023.07.22.550169. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
Actividad biológica
ADH-1 (0.2 mg/mL) blocks collagen I-mediated changes in pancreatic cancer cells, and is highly effective at preventing cell motility that is induced by expression of N-cadherin. ADH-1 (0, 0.1, 0.2, 0.5 and 1.0 mg/mL) induces apoptosis in a dose-dependent and N-cadherin-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ADH-1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model[2].
In A375, but not DM443 xenografts, ADH-1 treatment increases phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 229971-81-7
-
Appearance Solid
-
Peso molecular 570.69
-
Fòrmula C22H34N8O6S2
-
Color White to off-white
-
Sequence
Cys-His-Ala-Val-Cys
-
Sequence Shortening
CHAVC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * The compound is unstable in solutions, freshly prepared is recommended.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
Co-loaded lapatinib/PAB by ferritin nanoparticles eliminated ECM-detached cluster cells via modulating EGFR in triple-negative breast cancer. [Abstract]2022 Jun 20;13(6):557. PMID: 35725558 -
Oncogene
Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. [Abstract]2022 Nov;41(46):5020-5031. PMID: 36224341
ADH-1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Nov;41(46):5020-5031. [Abstract]
Cell growth was examined by XTT assay. Cells were treated with olaparib and/or N-cadherin inhibitor (ADH-1, 0-100 μM) at indicated doses for 72 hours.
-
Sci Rep
The RGD motif is involved in CD97/ADGRE5-promoted cell adhesion and viability of HT1080 cells. [Abstract]2019 Feb 6;9(1):1517. PMID: 30728423 -
J Cell Mol Med
Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function. [Abstract]2022 Apr;26(8):2392-2403. PMID: 35224849 -
iScience
Dendritic cells overcome Cre/Lox induced gene deficiency by siphoning cytosolic material from surrounding cells. [Abstract]2024 Feb 6;27(3):109119. PMID: 38384841 -
J Pain Res
Spinal N-Cadherin/CREB Signaling Contributes to Chronic Alcohol Consumption-Enhanced Postsurgical Pain. [Abstract]2020 Aug 12;13:2065-2072. PMID: 32848450
ADH-1 purchased from MedChemExpress. Usage Cited in: J Pain Res. 2020 Aug 12;13:2065-2072. [Abstract]
On day 20 after plantar incision and 5-week ethanol consumption, intrathecal injection of ADH-1 (40 μg), a specific N-cadherin inhibitor, significantly increased the decreased paw withdrawal threshold on the ipsilateral side compared to the vehicle control group.
ADH-1 purchased from MedChemExpress. Usage Cited in: J Pain Res. 2020 Aug 12;13:2065-2072. [Abstract]
On day 20 after plantar incision and 5-week ethanol consumption, intrathecal injection of ADH-1 (40 μg). The ADH-1 treatment had no effect on the paw withdrawal threshold on the contralateral side.
-
Biochem Biophys Res Commun
2019 Oct 5. pii: S0006-291X(19)31851-0. PMID: 31594642
ADH-1 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2019 Oct 5. pii: S0006-291X(19)31851-0. [Abstract]
HT1080 stable cells were cultured in the absence or presence of exherin (ADH-1, 100 μg/mL), and the level of MMP-9 was evaluated by MMP zymography.
-
-
-
bioRxiv
Dendritic Cells Overcome Cre/Lox Induced Gene Deficiency by Siphoning Material From Neighboring Cells Using Intracellular Monitoring-a Novel Mechanism of Antigen Acquisition. [Abstract]2023 Jul 25:2023.07.22.550169. PMID: 37546718
Solvente y solubilidad
DMSO : 100 mg/mL (175.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (35.05 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Animals are anesthetized, and 40 μL of a single cell suspension containing 50,000 cells is injected into the pancreas. Mice are randomized into treatment groups 10 days after surgery. For treatment, mice are injected intraperitoneally once per day with ADH-1 at 50 mg/kg in 100 μL PBS (×1 per day, ×5 per week for 4 weeks). For in vivo bioluminescence, D-Luciferin is administered by intraperitoneal injection. Data are acquired 20 min after injection using the IVIS system. Tumor growth is monitored every 10 days from day 10 to day 50 after surgery. Luciferase activity is quantified using the IVIS system. Two months after surgery, the mice are killed, and the pancreas, liver, lung, and disseminated nodules are harvested, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-μM sections are cut, mounted on slides, and stained with H&E using standard procedures. Sections are also stained for TUNEL. Sections are examined using a Zeiss Axioscop 40 microscope equipped with an AxioCam MR digital camera and software.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. [Content Brief]
[2]. Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. [Content Brief]
[3]. Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7523 mL | 8.7613 mL | 17.5226 mL | 43.8066 mL |
| 5 mM | 0.3505 mL | 1.7523 mL | 3.5045 mL | 8.7613 mL | |
| 10 mM | 0.1752 mL | 0.8761 mL | 1.7523 mL | 4.3807 mL | |
| 15 mM | 0.1168 mL | 0.5841 mL | 1.1682 mL | 2.9204 mL | |
| 20 mM | 0.0876 mL | 0.4381 mL | 0.8761 mL | 2.1903 mL | |
| 25 mM | 0.0701 mL | 0.3505 mL | 0.7009 mL | 1.7523 mL | |
| 30 mM | 0.0584 mL | 0.2920 mL | 0.5841 mL | 1.4602 mL | |
| 40 mM | 0.0438 mL | 0.2190 mL | 0.4381 mL | 1.0952 mL | |
| 50 mM | 0.0350 mL | 0.1752 mL | 0.3505 mL | 0.8761 mL | |
| 60 mM | 0.0292 mL | 0.1460 mL | 0.2920 mL | 0.7301 mL | |
| 80 mM | 0.0219 mL | 0.1095 mL | 0.2190 mL | 0.5476 mL | |
| 100 mM | 0.0175 mL | 0.0876 mL | 0.1752 mL | 0.4381 mL |
ADH-1 Related Classifications
HY-13541 Related Classifications
Powered by Bioz